Skip to main content
Premium Trial:

Request an Annual Quote

Axxam Selects Genedata's Software for Early-Stage Drug Discovery Projects

Premium

This week, Genedata said that Axxam, a Milan, Italy-based contract research firm, has selected its Genedata Screener software to support its customers' early-stage therapeutic discovery projects.

Genedata said that Axxam will use Genedata Screener to provide tailored data analysis for customer-specific screening and hit-to-lead services.

Specifically, Axxam will use Genedata Screener's Assay Analyzer module to import and process data from screening instruments using pre-defined protocols; its Condoseo module to fit dose-response curves and optimize them for large compound sets; and its Hit Profiler module to import biological results for compounds from different data sources and display them in tabular format.

In a statement, Michela Stucchi, who heads Axxam's screening technologies division, said the firm chose Genedata's software because it provides "a flexible high-throughput screening solution " that allows users to streamline and simplify complex assays.

Furthermore, "users with basic skills can easily load and analyze data for a fast quality check," she said.

Gendata's CEO, Othmar Pfannes, described the Axxam deal as "an important milestone" in his firm's product strategy, which includes expanding its sphere of influence beyond pharmaceutical companies and into the contract research market.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.